Drug Insights

Is Dasiglucagon approved by the FDA?

10 July 2024
3 min read

Dasiglucagon, marketed under the brand names Zegalogue Autoinjector and Zegalogue Prefilled Syringe, is an injectable medication used to treat severe hypoglycemia (very low blood sugar) in adults and children aged six years and older with diabetes.Dasiglucagon (Zegalogue) was approved by the U.S. Food and Drug Administration (FDA) on March 22, 2021. This approval introduced a new emergency treatment option for managing severe hypoglycemia, providing a fast-acting solution for diabetic patients in critical situations.

Mechanism of Action

Dasiglucagon works by stimulating the liver to release stored glucose into the bloodstream, thereby rapidly increasing blood sugar levels. It is administered subcutaneously (under the skin) and is designed for use in emergency situations where immediate action is required to prevent severe complications from hypoglycemia, such as seizures, coma, or death.

Usage and Administration

Dosage Form: Dasiglucagon is available as a subcutaneous solution with a concentration of 0.6 mg/0.6 mL.

Dosage Instructions:

  • Adults and Children (6 years and older): The recommended dose is 0.6 mg administered subcutaneously into the lower abdomen, buttocks, thigh, or outer upper arm. If there is no response within 15 minutes, a second dose of 0.6 mg may be given.

Administration:

  • Be familiar with the instructions for using dasiglucagon injections. Caregivers should know how to administer the medication before an emergency occurs.
  • After an injection, the patient should consume a fast-acting source of sugar, followed by a snack or small meal to stabilize blood sugar levels.

Side Effects and Warnings

Common Side Effects:

  • Nausea
  • Vomiting
  • Diarrhea
  • Headache
  • Injection site pain

Serious Side Effects:

  • Severe headache
  • Blurred vision
  • Rapid or pounding heartbeat
  • Ongoing low blood sugar symptoms (e.g., dizziness, sweating, fast heart rate)

Warnings:

  • Do not use dasiglucagon if you have an insulinoma (pancreatic tumor) or pheochromocytoma (adrenal gland tumor).
  • Be cautious if you have chronic low blood sugar, adrenal gland problems, or a latex allergy.
  • Follow your doctor's instructions closely to manage your diet, medication, and exercise routines to prevent severe hypoglycemia.

Storage:

  • Store dasiglucagon in the refrigerator, away from the cooling element. Do not freeze.
  • It can also be stored at room temperature for up to 12 months but must be used within this period.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

GPCR Family Anticancer Targets and Marketed Therapeutic Drugs (Part 2)
Drug Highlight
6 min read
GPCR Family Anticancer Targets and Marketed Therapeutic Drugs (Part 2)
10 July 2024
This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.
Read →
Is Ponesimod approved by the FDA?
Drug Insights
3 min read
Is Ponesimod approved by the FDA?
10 July 2024
Ponvory (ponesimod) was approved by the U.S. Food and Drug Administration (FDA) on March 18, 2021.
Read →
iTeos Announces First Patient Dosed in Phase 3 GALAXIES Lung-301 Trial, Receives $35 Million from GSK
Latest Hotspot
3 min read
iTeos Announces First Patient Dosed in Phase 3 GALAXIES Lung-301 Trial, Receives $35 Million from GSK
10 July 2024
iTeos Reports Initial Patient Dosed in GALAXIES Lung-301 Phase 3 Trial, Securing $35 Million Milestone Payment from GSK.
Read →
Is Idecabtagene vicleucel approved by the FDA?
Drug Insights
3 min read
Is Idecabtagene vicleucel approved by the FDA?
10 July 2024
Abecma (idecabtagene vicleucel) received approval from the U.S. Food and Drug Administration (FDA) on March 26, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.